Table 2.
Clinicopathological characteristics of the RA patients used for the miRNA array.
| Characteristics | Before | 3 Months After * | 1 Year After |
|---|---|---|---|
| Number of patients | 10 | 9 | 10 |
| Sex, male/female | 2/8 | 2/7 | 2/8 |
| Age (years) | 54.7 ± 13.4 | 55.9 ± 13.7 | 54.7 ± 13.4 |
| Disease duration (months) | 11.6 ± 7.2 | 12.0 ± 7.5 | 11.6 ± 7.2 |
| ESR (mm/h) | 39.4 ± 24.1 | 24.3 ± 16.4 | 20.8 ± 12.4 |
| C-reactive protein (mg/L) | 1.19 ± 1.45 | 0.30 ± 0.61 | 0.23 ± 0.39 |
| MMP3 (ng/mL) | 166 ± 137 | 212 ± 152 | 143 ± 97 |
| DAS28-CRP | 4.20 ± 1.15 | 2.66 ± 0.86 | 1.94 ± 0.67 |
| Remission (<2.3) | 0 | 3 | 7 |
| low disease activity (<2.7) | 0 | 2 | 2 |
| moderate disease activity (2.7–4.1) | 5 | 4 | 1 |
| high disease activity (>4.1) | 5 | 0 | 0 |
* One patient’s data was missing. All values are reported as the mean ± standard deviation. ESR, erythrocyte sedimentation ratio; MMP3, matrix metalloproteinase-3; DAS28-CRP, Disease Activity Score 28 joint count with C-reactive protein.